ArticleInfluenza and other respiratory viruses2026
Circulation of Influenza and Other Respiratory Viruses in Tunisia, 2022-2023 Season.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInfluenza sentinel surveillance has been ongoing in Tunisia since 1999. We describe the epidemiology of respiratory viruses during 2022-2023, the first season to include testing for other respiratory viruses, such as respiratory syncytial virus (RSV).
methodsWe analyzed weekly surveillance data from severe acute respiratory infection (SARI) inpatients and influenza-like illness outpatients from 11 hospitals and 85 clinics in Tunisia. Nasopharyngeal specimens and demographic, clinical, and vaccination data were collected. Specimens were tested by rRT-PCR for influenza, SARS-CoV-2, RSV, and 18 other respiratory viruses. Descriptive statistics were used to summarize case characteristics; group differences were assessed using chi-squared or Fisher's exact tests.
results2038 specimens were collected from unique patients; 1231 (60.4%) were positive for ≥ 1 respiratory virus and 200 (16.2%) were positive for ≥ 2 viruses. Influenza was the most detected (n = 445; 21.8%), followed by rhinovirus (n = 301, 14.8%), RSV (n = 255, 12.5%), and SARS-CoV-2 (n = 125, 6.1%). Among SARI cases, infections with influenza and SARS-CoV-2 were more common in adults ≥ 50 years (61.8% and 71.4%, respectively), while children < 2 years had higher RSV prevalence (83.0%, adjusted p-value = 0.004). 4.9% of patients received a recent influenza vaccine.
conclusionThe burden of respiratory viruses varied by age, with RSV being more prevalent among younger children and SARS-CoV-2 and influenza being more prevalent among older adults. Ongoing sentinel surveillance is essential to monitor priority respiratory pathogens, particularly those with available public health interventions, such as vaccination, to enable timely action and reduce disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.